ADDovenom: Novel Snakebite Therapy Platform of Unparalleled Efficacy, Safety and Affordabillity
About Addvenom
Snakebites can be life-threatening when venom toxins are injected and enter the bloodstream. In areas where immediate access to specialised medical care is limited, bites by venomous snakes cause many thousands of deaths each year.
The EU-funded ADDovenom Project will use an innovative platform enabling generation of new snakebite treatment, based on a new disruptive protein-based nanoscaffold called ADDomer© – a megadalton- sized, thermostable synthetic virus-like particle with 60 high-affinity binding sites to neutralise and eliminate venom toxins from the bloodstream.
ADDovenom combines pioneering proteomics, transcriptomics and bioinformatics focusing on snake toxins provoking the most challenging syndromes like haemorrhage and paralysis. The aim is to develop first-in-class neutralising superbinders for snakebite therapy of unprecedented efficacy against the most prevalent Sub-Saharan snakes.
ADDomer©: Synthetic multiepitope display scaffold for next generation vaccines.
Research
The project comprises several technological challenges (rational design of new antigens as consensus toxins/epitope strings, design of an ADDobody library) and high-risk research (in vitro selection of new binders from a novel protein scaffold).
Latest news
ADDovenom / BBI webinar with Prof Gérard Lambeau
On 5 May 2021, ADDovenom teamed up with colleagues at the Bristol BioDesign Institute to organise a webinar with Professor Gérard Lambeau from CNRS (Centre national de la recherche scientifique)....
IMI-EU funding to accelerate Advanced Therapy Medicinal Products
iBET participates in ARDAT – Accelerating Research and Innovation for Advanced Therapies, a project which aims to standardize and accelerate the development of Advanced Therapy Medicinal Products...
Paula Alves elected for US National Academy of Engineering
Congratulations to ADDovenom project partner Paula Alves (CEO of iBET - Instituto de Biologia Experimental e Tecnológica), who has been elected foreign member of the National Academy of Engineering...
French newspaper La Provence writes about ADDovenom
La Provence, the most read newspaper in the south of France, devoted a page of its 7 January 2021 edition the ADDovenom project. The article includes an interview with Renaud Vincentelli from...
Loïc Quinton secures F.R.S – FNRS funding for new ‘Venoms4Liège’ project
Congratulations to ADDovenom team member Loïc Quinton (University of Liège), who has been awarded four years of funding by F.R.S - FNRS for the project: "Venoms4Liège: From mortal mixtures to...
ADDovenom: an innovative treatment to reduce deaths due to snake bites
A new European project, led by the University of Bristol and involving the Mass Spectrometry Laboratory (MolSys Research Unit / Faculty of Sciences) of the ULiège, will develop a new curative...
Prof Rob Harrison on LSTM’s research activity and impacts on tropical snakebite
The former head of LSTM's Centre for Snakebite Research & Interventions (CSRI), Professor Rob Harrison, on behalf of Professors David Theakston, David Lalloo and Nick Casewell, has given a talk...
New type of antivenom to reduce 100,000 fatalities each year from venomous snake bites being developed by Bristol scientists
A new approach of treating life-threatening snake bites responsible for around 100,000 deaths globally each year is being pioneered by an international research consortium led by University of...
Experts
ADDovenom synergistically combines unique expertise across a range of techniques and scientific disciplines, towards the objective to develop easy to produce, first-in-class neutralizing superbinders for snakebite therapy.